Although our data showed the significant elevation of tissue and plasma BST2 levels in CRC patients compared to normal controls, how BST2, a type II transmembrane protein, can be released from tumor tissue into the blood circulation remains unclear at present. The gene discussed is BST2; the disease is neoplasm.